image credit- shutterstock
Zylox-Tonbridge, a Hong Kong-listed medical technology company focused on neuro-and peripheral vascular interventional products and solutions, has entered into a definitive agreement to acquire a Germany-based medical technology company, Optimed Medizinische Instrumente GmbH, specialising in research and development, production and distribution of medical devices for minimally invasive therapy worldwide, in multiple steps.
Under the terms of the agreement, Zylox-Tonbridge has the option to acquire the entire equity interest in Optimed from its existing shareholders.
Optimed's dedicated venous stents are supported by high-evidence clinical trials such as the sinus-Venous, is supported by robust clinical evidence from STEVECO, the first prospective, randomized, multicenter trial in this chronic deep venous obstruction setting, which demonstrated significant improvements in quality of life and clinical severity compared with conservative treatment.
The acquisition of Optimed accelerates Zylox-Tonbridge's global expansion by establishing a unified platform spanning research and development, manufacturing, and commercialization. By integrating both companies' sales networks and leveraging Optimed's long-standing relationships with European clinical experts, Zylox-Tonbridge will be positioned to bring products to market more efficiently and expand its global reach.
Furthermore, this partnership is also expected to generate significant operational synergies, supported by an expanded manufacturing base in Germany to ensure a high-quality, reliable supply of innovative medical solutions for European and global markets. Following the closing of the transaction, Zylox-Tonbridge will integrate its sales, marketing, and customer service teams with those of Optimed to create one unified global commercial organization. Rüdiger Hausherr will continue to serve as Chief Executive Officer of Optimed and will report to Jonathon Zhong Zhao, Chairman and Chief Executive Officer of Zylox-Tonbridge.
